close
close

Increased Genmab capital as a result of employee mandate exercise 25.02.25

Posted on by Online Niel
Increased Genmab capital as a result of employee mandate exercise 25.02.25

The announcement of the company

Copenhagen, Denmark; February 25, 2025 – Genmab a/s. (NASDAQ: GMAB) will increase its share capital by 10,058 shares due to the exercise of employees.

The growth is done without pre -emination rights for the existing shareholders of the company or other persons. Actions are subscribed in cash at the next price per share in nominal DKK 1:

709 Actions at DKK 962.00,
3.729 Actions at 1.025.00 DKK,
415 shares at 1.050.00 DKK,
200 shares at DKK 1,147.50,
335 Actions at DKK 1.161.00,
3.116 Actions at 1.210.00 DKK and
1,554 shares at 1,362.50 DKK.

The receipts to the company are about 11.4 million DKK. The growth corresponds to about 0.02% of the company’s share capital.

New actions are ordinary actions without special rights and are freely transferable tools. The new actions give the rights to dividends and other rights in relation to the subscription company. The new actions will be listed on Nasdaq Copenhagen after registering at the Danish business authority. Capital increase is expected to be completed shortly.

According to Section 32 of the Law on Danish capital markets no. 198 of February 26, 2024, it is announced by the presence that the total nominal value of the Genmab A/S share capital after the increase of the capital is 66,197.244 DKK, which consists of 66.197.244 Actions of a nominal value of DKK 1 each, corresponding to 66.197.244 votes.

About Genmab
Genmab is an international biotechnology company with a main purpose to guide its unstoppable team to strive to improve the lives of patients with innovative and differentiated antibodies. For more than 25 years, his passionate, innovative and collaborative team has invented the technological platforms of the following generation antibodies and has supported translational, quantitative and data sciences, resulting in a property pipe, including Bispecific commitments with T cells, conjugated by Modulator antibody-drugs of immune control and improved antibodies with effective functions. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with sock antibody (KYSO)®.?

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence in North America, Europe and Asia Pacific. For more information please visit Genmab.com? And it follows LinkedIn and X.

Contact:
Marisol Peron, senior vice president, global communications and corporate business
T: +1 609 524 0065; E [email protected]

Andrew Carlsen, vice -president, head of investors relationships
T: +45 3377 9558; E [email protected]

This company’s advertisement contains statements before. The words “believe”, “wait”, “anticipate”, “intend” and “plan” and similar expressions identify declarations of advancement. Real results or performance may differ significantly from any future results or performance expressed or involved by such statements. Important factors that could determine our real results or performance to differ significantly, among others, the risks associated with the preclinical and clinical development of the products, uncertainties related to the result and conduct of clinical studies, including unforeseen safety problems, uncertainties related to the manufacture of Products, lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to the area and markets Our business, our inability to attract and keep properly qualified, non -existent or lack of protection protection to our patents and our property rights, our relationships with affiliated entities, changes and evolutions of technology that can make the products or technologies. ours to be outdated and other factors. For an additional discussion of these risks, please see the risk management sections in the latest financial reports of Genmab, which are available on www.genmab.com
and the risk factors included in the most recent annual report of GENMAB on form 20-F and other records with the US Security and Exchange Commission (SEC), which are available at www.sec.gov. Genmab assumes no obligation to update or review advance statements in this company’s ad, nor to confirm these statements to reflect further events or circumstances after the date made or in relation to the real results, unless requested by law.

Genmab A/S and/or its branches hold the following commercial brands: Genmab®; The GenMab Logo in the form of y®; Genmab in combination with GenMab logo in the form of y®; Humax®; Duobody®; Hexabody®; Duohexabody®Hexelect® and Kyso®.

The announcement of the company no. 05
CVR no. 2102 3884
Code lei 529900mtjpdppe4MHJ122

Genmab a/s.
Carl Jacobsens Vej 30
2500 Valby
Denmark